A new drug developed to treat rheumatoid arthritis may be given to the most seriously ill Covid-19 patients, if a clinical trial now under way in Manchester proves successful.
Farhan Hamid, 41, has become the first British coronavirus patient to receive the drug, called otilimab, as part of a study run by Manchester Royal Infirmary.
“The research aims to establish whether otilimab can treat severe lung disease developed as a result of Covid-19,” says Sky News.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Dr Andy Martin, who is running the trial, said Hamid, from south Manchester, had been enrolled in the study because he was experiencing severe difficulty breathing. The experimental drug could “ease the effect of coronavirus on the lungs, dampening the impact of the virus on the immune system”, Martin explained.
Funded by the drug’s manufacturer, Glaxo SmithKline (GSK), the trial has “been given urgent public health research status by the Department of Health and Social Care”, the Daily Mirror reports.
Hospitals from all over the world, including five in the UK, will eventually take part in the tests, which will involve a total of 800 patients. Trials have already begun in the US.
“Those taking part will be allocated into two groups at random, with half receiving a one-hour, single infusion of otilimab,” says the Daily Mail. The other group will get “placebo intravenous therapy, in addition to standard care”.
Christopher Corsico of GSK said the drug is believed to help patients who are experiencing the most severe reaction to Covid-19.
“We know that some Covid-19 patients experience an overreaction of their immune system - sometimes referred to as cytokine storm - which can lead to hospitalisation or death,” he said.
“We believe that otilimab might be able to help counter or calm this process.”
Continue reading for free
We hope you're enjoying The Week's refreshingly open-minded journalism.
Subscribed to The Week? Register your account with the same email as your subscription.
-
'The United States needs to up its game'Instant opinion Opinion, comment and editorials of the day
-
'Accepting defeat is Rishi Sunak's only hope of victory'
Instant Opinion Opinion, comment and editorials of the day
-
Royal family website attacked by Russian hackers
Speed Read Pro-Kremlin group claim responsibility just two weeks after King Charles condemns invasion of Ukraine
-
How do we calculate mass deaths?
The Explainer Recent revisions to 9/11, Libyan flood and Covid-19 death tolls raise questions over estimates
-
Fixing the NHS workforce
The Explainer There are roughly 112,000 vacant posts in NHS England with nearly one in ten posts unfilled
-
You can now get a new Covid booster shot. Should you?
Unless you are old or otherwise at high risk, it isn't a 'slam dunk'
-
Surgery faces ‘MeToo moment’ as female staff assaulted while operating
Two-thirds of women surgeons claim to have been sexually harassed and a third alleged assaults
-
Is it time to mask up again?
Today's Big Question A rise in Covid-19 cases brings back the possibility of mask mandates
-
What does UK’s first womb transplant mean for future of fertility?
Today's Big Question Procedure could be offered more widely including to transgender people
-
The NHS plan for virtual wards to beat winter crisis
feature Patients with respiratory infections to be given wearable devices that allow doctors to monitor them at home
-
Understanding the new Covid-19 variant, Eris
Speed Read The formally named EG.5 is making the rounds, but we don't have to worry just yet
